Biomarkers in endometrial cancer: Possible clinical applications (review)

Oncology Letters

Volumn 3, Issue 6, 2012, Pages 1175-1180

  Banno, Kouji ^a   Kisu, Iori ^a   Yanokura, Megumi ^a   Tsuji, Kosuke ^a   Masuda, Kenta ^a   Ueki, Arisa ^a   Kobayashi, Yusuke ^a   Yamagami, Wataru ^a   Nomura, Hiroyuki ^a   Tominaga, Eiichiro ^a   Susumu, Nobuyuki ^a   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Biomarker; DNA microarray; Endometrial cancer; K ras; Prognosis; PTEN

Indexed keywords

AFLIBERCEPT; BETA CATENIN; BEVACIZUMAB; CADHERIN; CETUXIMAB; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GEFITINIB; HORMONE RECEPTOR; K RAS PROTEIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MISMATCH REPAIR PROTEIN; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P21; TEMSIROLIMUS; TRANSCRIPTION FACTOR EZH2; TRASTUZUMAB; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN RECEPTOR; WORTMANNIN;

ANEUPLOIDY; CANCER PROGNOSIS; CARCINOGENESIS; DIAGNOSTIC ACCURACY; DNA MICROARRAY; DRUG EFFICACY; ENDOMETRIUM; ENDOMETRIUM CANCER; GENE EXPRESSION; GENE MUTATION; HUMAN; MENOPAUSE; MICROSATELLITE INSTABILITY; ONCOGENE; PLOIDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84859470538     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.654     Document Type: Review

References (56)

1. World Health Organization, International Agency for Research on Cancer: World Cancer Report. IARC Press, Lyon, 2003.
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Endometrial cancer. Lancet 366: 491-505, 2005.
3. Engelsen IB, Akslen LA and Salvesen HB: Biologic markers in endometrial cancer treatment. APMIS 117: 693-707, 2009.
4. Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10: 789-799, 2004.
5. Enomoto T, Inoue M, Perantoni AO, Terakawa N, Tanizawa O and Rice JM: K-ras activation in neoplasms of the human female reproductive tract. Cancer Res 50: 6139-6145, 1990.
6. Caduff RF, Johnston CM and Frank TS: Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 146: 182-188, 1995.
7. Mammas IN, Zafiropoulos A and Spandidos DA: Involvement of the ras genes in female genital tract. Int J Oncol 26: 1241-1255, 2005.
8. Cully M, You H, Levine AJ and Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192, 2006.
9. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT and Wu W: Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22: 3126-3132, 2004.
10. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK and Clarke-Pearson DL: Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164: 15-21, 1991.
11. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N and Copeland L: HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24: 2376-2385, 2006.
12. Oda K, Stokoe D, Taketani Y and McCormick F: High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669-10673, 2005.
13. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Stefansson IM and Getz G: Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 106: 4834-4839, 2009.
14. Soufla G, Sifakis S and Spandidos DA: FGF2 transcript levels are positively correlated with EFG and IGF-1 in the malignant endometrium. Cancer Lett 259: 146-155, 2008.
15. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC and Hatton C: Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 105: 8713-8717, 2008.
16. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R and Yamada KM: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280: 614-617, 1998.
17. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED and Akslen LA: PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 91: 22-26, 2001.
18. Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, MacDonald ND and Ryan A: Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol 25: 1615-1623, 2004.
19. Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC and Barrett JC: Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res 58: 2500-2503, 1998.
20. Prat J, Gallardo A, Cuatrecasas M and Catasus L: Endometrial carcinoma: pathology and genetics. Pathology 39: 72-87, 2007.
21. Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
22. Soong R, Robbins PD, Dix BR, Grieu F, Lim B and Knowles S: Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 27: 1050-1055, 1996.
23. Risinger JI, Dent GA, Ignar-Trowbridge D, McLachlan JA, Tsao MS and Senterman M: p53 gene mutations in human endometrial carcinoma. Mol Carcinog 5: 250-253, 1992.
24. Kihana T, Hamada K, Inoue Y, Yano N, Iketani H and Murao S: Mutation and allelic loss of the p53 gene in endometrial carcinoma. Cancer 76: 72-78, 1995.
25. Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ and Iacopetta BJ: Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 74: 562-567, 1996.
26. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD and Karlan BY: HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 85: 729-734, 1995.
27. Lax SF, Kendall B, Tashiro H, Slebos RJ and Hedrick L: The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88: 814-824, 2000.
28. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB and Herman JG: In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 96: 12754-12759, 1999.
29. Nakashima R, Fujita M, Enomoto T, Haba T, Yoshino K and Wada H: Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer 80: 458-467, 1999.
30. Salvesen HB, Das S and Akslen LA: Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 6: 153-159, 2000.
31. Milde-Langosch K, Riethdorf L, Bamberger AM and Löning T: P16/MTS1 and pRB expression in endometrial carcinomas. Virchows Arch 434: 23-28, 1999.
32. Ionov Y, Peinado MA, Malkhosyan S, Shibata D and Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363: 558-561, 1993.
33. Lynch HT, Smyrk T and Lynch JF: Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). Int J Cancer 69: 38-43, 1996.
34. Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD and Frank TS: Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 148: 1671-1678, 1996.
35. Esteller M, Levine R, Baylin SB, Ellenson LH and Herman JG: MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17: 2413-2417, 1998.
36. Catasus L, Machin P, Matias-Guiu X and Prat J: Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol 29: 1160-1164, 1998.
37. Arvanitis DA, Angelakis E, Koumantakis EE and Spandidos DA: Allelic imbalance in hMLH1 or BRCA2 loci associated with response of cervical and endometrial cancer to radiotherapy. Int J Mol Med 10: 55-63, 2002.
38. Horree N, Van Diest PJ, Sie-Go DM and Heintz AP: The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum Pathol 38: 1232-1238, 2007.
39. Sakuragi N, Salah-eldin AE, Watari H, Itoh T, Inoue S and Moriuchi T: Bax, Bcl-2, and p53 expression in endometrial cancer. Gynecol Oncol 86: 288-296, 2002.
40. Ohkouchi T, Sakuragi N, Watari H, Nomura E, Todo Y and Yamada H: Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol 187: 353-359, 2002.
41. Ito K, Utsunomiya H, Yaegashi N and Sasano H: Biological roles of estrogen and progesterone in human endometrial carcinoma - new developments in potential endocrine therapy for endometrial cancer. Endocr J 54: 667-679, 2007.
42. McDonnell DP and Norris JD: Connections and regulation of the human estrogen receptor. Science 296: 1642-1644, 2002.
43. Shang Y: Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 6: 360-368, 2006.
44. van der Putten HW, Baak JP, Koenders TJ, Kurver PH, Stolk HG and Stolte LA: Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma. Cancer 63: 1378-1387, 1989.
45. Susini T, Amunni G, Molino C, Carriero C, Rapi S and Branconi F: Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: DNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors. Cancer 109: 882-890, 2007.
46. Risinger JI, Maxwell GL, Chandramouli GV, et al: Microarray analysis reveals distinct gene expression profiles among different histologic subtypes of endometrial cancer. Cancer Res 63: 72-87, 2003.
47. Planagumà J, Díaz-Fuertes M, Gil-Moreno A, et al: A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res 64: 8846-8853, 2004.
48. Colas E, Perez C, Cabrera S, et al: Molecular markers of endometrial carcinoma detected in uterine aspirates. Int J Cancer 129: 2435-2444, 2011.
49. Prat J: Prognostic parameters of endometrial carcinoma. Hum Pathol 35: 649-662, 2004.
50. Yamazawa K, Seki K, Matsui H, Kihara M and Sekiya S: Prognostic factors in young women with endometrial carcinoma: a report of 20 cases and review of literature. Int J Gynecol Cancer 10: 212-222, 2000.
51. Singh M, Zaino RJ, Filiaci VJ and Leslie KK: Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 106: 325-333, 2007.
52. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT and Wu W: Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22: 3126-3132, 2004.
53. Salvesen HB, Iversen OE and Akslen LA: Prognostic significance of angiogenesis and Ki-67, p53 and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17: 1382-1390, 1999.
54. Salvesen HB, Stefansson I, Kalvenes MB, Das S and Akslen LA: Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 94: 2185-2191, 2002.
55. Nordström B, Strang P, Bergström R, Nilsson S and Tribukait B: A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Cancer 78: 1942-1951, 1996.
56. Al Kushi A, Lim P, Quino-Parsons C and Gilks CB: Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 15: 365-371, 2002.